Plain-English translation of NCT05099770 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes Mellitus research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment called rilparencel, which involves injecting specially prepared kidney cells directly into your kidney to help protect and restore kidney function. The treatment is being tested in people who have both type 2 diabetes and chronic kidney disease. Half of participants will receive the actual treatment, while the other half will receive a sham procedure (a fake procedure that looks and sounds real) so researchers can fairly compare how well the treatment works.
Chronic kidney disease in people with diabetes is a serious condition that can gradually worsen over time. Current medications help slow this process, but they don't stop it completely. This medication aims to directly repair kidney damage and slow the decline in kidney function using the body's own cells.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive the actual treatment with rilparencel injections or a sham procedure. If you receive the treatment, you will have a kidney biopsy (a small tissue sample) and your first injection, followed by a second injection into your other kidney about 12 weeks later. All participants will be followed until the study ends, with regular clinic visits to monitor your kidney function and overall health. The study involves multiple visits over an extended period to track how well the treatment works.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States